MEMBER LOGIN

Not yet a member? See the benefits of becoming one.

Category Archive: CDC News

Most Measles Cases in 25 Years: Is This the End of Measles Elimination in the United States?

In 2000, measles was declared eliminated from the United States. However, the number of measles cases so far in 2019 exceeds the number of annual

CDC COCA Digest: April 3, 2019

CDC COCA Digest: April 3, 2019

Centers for Disease Control and Prevention (CDC) sent this bulletin at 04/03/2019 04:38 PM

Outbreak of Multidrug-Resistant SalmonellaInfections Linked to Raw Turkey Products

CDC and public health and regulatory officials in several states are investigating a multistate outbreak of Salmonella Reading infections linked to raw turkey products. The U.S. Department

CDC Health Alert Network (HAN) Advisory

CDC HAN 412: Outbreak of Hepatitis A Virus (HAV) Infections among Persons Who Use Drugs and Persons Experiencing Homelessness

June 11, 2018: This HAN alerts

Multistate Outbreak of Cyclosporiasis Linked to Del Monte Fresh Produce Vegetable Trays

The U.S. Food and Drug Administration (FDA) along with the Centers for Disease Control and Prevention (CDC) and state and local officials have been

Health Alert Network (HAN) No. 403 – Potential for Falsely Low Blood Lead Test Results from LeadCare® Analyzers

The U.S. Food and Drug Administration (FDA) has issued a safety communication warning about the use of Magellan Diagnostics’ LeadCare® analyzers (LeadCare, LeadCare II, LeadCare Ultra and LeadCare Plus) with venous blood samples because they might result in falsely low test results. FDA is now advising that Magellan Diagnostics’ LeadCare® analyzers should no longer be used with venous blood samples. The safety alert does not apply to capillary blood lead test results collected by fingerstick or heelstick. The purpose of this Health Advisory is to notify state and local health departments, healthcare providers, and laboratories about CDC’s re-testing guidance in light of the safety alert.

Health Alert Network (HAN) No. 403 – Potential for Falsely Low Blood Lead Test Results from LeadCare® Analyzers

The U.S. Food and Drug Administration (FDA) has issued a safety communication warning about the use of Magellan Diagnostics’ LeadCare® analyzers (LeadCare, LeadCare II, LeadCare Ultra and LeadCare Plus) with venous blood samples because they might result in falsely low test results. FDA is now advising that Magellan Diagnostics’ LeadCare® analyzers should no longer be used with venous blood samples. The safety alert does not apply to capillary blood lead test results collected by fingerstick or heelstick. The purpose of this Health Advisory is to notify state and local health departments, healthcare providers, and laboratories about CDC’s re-testing guidance in light of the safety alert.

Public Health Matters Blog – National Hurricane Preparedness Week (May 7-13, 2017): It Only Takes One!

As the saying goes, “all politics are local.” The same goes for hurricanes. A busy hurricane season is not just defined by the total number of hurricanes in a season, but rather if any hurricane hits your local community. It only takes one. This mantra provides the impetus every May for the National Oceanic and Atmospheric Administration (NOAA) and its partners to participate in the National Hurricane Preparedness Week. The goal of National Hurricane Preparedness Week is to motivate communities, businesses, and individuals to know their risks, take steps to prepare, and encourage their loved ones, neighbors, and social network to do the same.

Health Alert Network (HAN) No. 402 – Prolonged IgM Antibody Response in People Infected with Zika Virus: Implications for Interpreting Serologic Testing Results for Pregnant Women

In July 2016, CDC issued Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure – United States, July 2016 (https://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm) that includes Zika virus immunoglobulin M (IgM) testing of pregnant women. However, some flavivirus infections can result in prolonged IgM responses (>12 weeks) that make it difficult to determine the timing of infection, especially in testing of asymptomatic people. Emerging epidemiologic and laboratory data indicate that Zika virus IgM can persist beyond 12 weeks in a subset of infected people. Therefore, detection of IgM may not always indicate a recent infection. Although IgM persistence could affect IgM test interpretation for all infected people, it would have the greatest effect on clinical management of pregnant women with a history of living in or traveling to areas with Zika virus transmission. Pregnant women who test positive for IgM antibody may have been infected with Zika virus and developed an IgM response before conception.

Health Alert Network (HAN) No. 402 – Prolonged IgM Antibody Response in People Infected with Zika Virus: Implications for Interpreting Serologic Testing Results for Pregnant Women

In July 2016, CDC issued Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure – United States, July 2016 (https://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm) that includes Zika virus immunoglobulin M (IgM) testing of pregnant women. However, some flavivirus infections can result in prolonged IgM responses (>12 weeks) that make it difficult to determine the timing of infection, especially in testing of asymptomatic people. Emerging epidemiologic and laboratory data indicate that Zika virus IgM can persist beyond 12 weeks in a subset of infected people. Therefore, detection of IgM may not always indicate a recent infection. Although IgM persistence could affect IgM test interpretation for all infected people, it would have the greatest effect on clinical management of pregnant women with a history of living in or traveling to areas with Zika virus transmission. Pregnant women who test positive for IgM antibody may have been infected with Zika virus and developed an IgM response before conception.

« Older Entries

© Copyright 2014 Nedrix